Dr. Piera Federico, from Benevento, Italy, earned an honors degree in medicine and surgery at Università Cattolica of Sacro Cuore-Rome; she attended graduate school in oncology at the University of Naples obtaining the highest marks with honors. She participated in the oncology training course at the National Cancer Institute in Bethesda. At University" Vanvitelli" in Naples, she received her PhD (international doctorate programme) in molecular oncology and clinical endocrinology with honors. In 2019, she obtained her master’s degree in immuno-oncology at UOC Immunoterapia of Professor M. Maio. She has several publications in international journals and has participated in international clinical studies. Since 2019, she has been working at the oncology department of the Ospedale del Mare (Naples, Italy) where she heads the multidisciplinary group of hepatocarcinoma (HCC) and where she is the principal investigator of Phase III studies of immunotherapy in HCC. She is co-author in the following: -“Immunotherapy of HCC” to be included in the upcoming second edition of Cancer Immunotherapy Principles and Practice edited by Lisa H. Butterfield, PhD, Howard L. Kaufman, MD, FACS, and Francesco M. Marincola, MD -Immune checkpoint inhibitor plus anti-vascular endothelial growth factor: Atezolizumab plus bevacizumab as the new first-line standard of care: Chapter 8 included in the volume of Immunotherapy combination strategies in unresectable HCC: L. Rimassa - Ed. Minerva Medica